ArticleScientific reports2026
Investigating the protective effect of zinc oxide-gallic acid nanoparticles against depression like behavior and memory impairment in animals treated with D-galactose.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
D-galactose-induced aging is an invincible phenomenon causing neurological disorders like depression, memory impairment etc., In the experiment, 30 male rats were allocated on an arbitrary basis into five groups (n = 6): (i) Water + Water; (ii) Water + D-galactose; (iii) D-galactose + Gallic acid; (iv) D-galactose + ZnO NPs, and (v) D-galactose + ZnO-gallic acid NPs. Each group received its respective treatment intraperitoneally, once daily for 28 days, according to body weight. After the treatment period, on the 29th and 30th days, behavioural tests Forced Swimming test and Morris Water Maze tests were performed for the assessment of depression and memory function, respectively. After that, decapitation was performed on the 31st day, and the rat brains were extracted and stored for biochemical, neurochemical, and histopathological analysis. Results showed that D-galactose-induced depression-like effects and impaired memory. D-galactose induced an increase in oxidative stress and inflammatory markers while decreasing antioxidant enzymes. The activity of AChE also increased by D-galactose administration. Histopathological assessment revealed deteriorative alterations in the brain. All of these behavioral, biochemical, neurochemical, and histopathological alterations caused by D-galactose were regulated by ZnO-gallic acidNPs. It is concluded that ZnO-gallic acidNPs, a nanocomposite, could be a better remedy for aging-related depression and cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.